354 related articles for article (PubMed ID: 35543863)
21. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study.
Farroni C; Aiello A; Picchianti-Diamanti A; Laganà B; Petruccioli E; Agrati C; Garbuglia AR; Meschi S; Lapa D; Cuzzi G; Petrone L; Vanini V; Salmi A; Altera AMG; Repele F; Grassi G; Bettini A; Vita S; Mariano A; Damiani A; Infantino M; Grossi V; Manfredi M; Niccoli L; Puro V; Rosa RD; Salemi S; Sesti G; Scolieri P; Bruzzese V; Benucci M; Cantini F; Nicastri E; Goletti D
Int J Infect Dis; 2022 Dec; 125():195-208. PubMed ID: 36328289
[TBL] [Abstract][Full Text] [Related]
22. Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020-2022): A retrospective longitudinal SARS-CoV-2 serological surveillance.
De Pace V; Bruzzone B; Ricucci V; Calcavecchia N; Guarona G; Giberti I; Costa E; Ogliastro M; Galano B; Nigro N; Murgia D; Nanni L; Orsi A
Hum Vaccin Immunother; 2023 Aug; 19(2):2258632. PubMed ID: 37724517
[TBL] [Abstract][Full Text] [Related]
23. Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs.
Saltoğlu N; Dinç HÖ; Balkan İİ; Can G; Özbey D; Beytur AN; Keskin E; Budak B; Aydoğan O; Mete B; Karaali R; Ergin S; Kocazeybek B
Diagn Microbiol Infect Dis; 2022 Oct; 104(2):115758. PubMed ID: 35878507
[TBL] [Abstract][Full Text] [Related]
24. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
25. Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection.
Pratò S; Paladino ME; Riva MA; Cavallero A; Latocca R; Biondi A; Bonfanti P; Belingheri M
Acta Biomed; 2022 Jan; 92(6):e2021464. PubMed ID: 35075063
[TBL] [Abstract][Full Text] [Related]
26. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
27. Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children.
Ricciardi A; Zelini P; Cassaniti I; Avanzini MA; Colaneri M; De Silvestri A; Baldanti F; Bruno R
Int J Infect Dis; 2022 Sep; 122():905-909. PubMed ID: 35803470
[TBL] [Abstract][Full Text] [Related]
28. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
29. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers.
Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A
Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766
[TBL] [Abstract][Full Text] [Related]
30. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
31. Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.
Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI
J Med Virol; 2022 Oct; 94(10):4719-4726. PubMed ID: 35655438
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
Front Immunol; 2022; 13():960001. PubMed ID: 36311767
[TBL] [Abstract][Full Text] [Related]
33. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
34. Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2.
Malipiero G; D'Agaro P; Segat L; Moratto A; Villalta D
Clin Chim Acta; 2022 Jan; 524():11-17. PubMed ID: 34843705
[TBL] [Abstract][Full Text] [Related]
35. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Gestational Age at BNT162b2 mRNA Vaccination on Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Levels.
Rottenstreich A; Zarbiv G; Oiknine-Djian E; Vorontsov O; Zigron R; Kleinstern G; Wolf DG; Porat S
Clin Infect Dis; 2022 Aug; 75(1):e603-e610. PubMed ID: 35171998
[TBL] [Abstract][Full Text] [Related]
37. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan.
Igari H; Asano H; Murata S; Yoshida T; Kawasaki K; Kageyama T; Ikeda K; Koshikawa H; Okuda Y; Urushihara M; Chiba H; Yahaba M; Taniguchi T; Matsushita K; Yoshino I; Yokote K; Nakajima H
J Infect Chemother; 2022 Nov; 28(11):1483-1488. PubMed ID: 35870791
[TBL] [Abstract][Full Text] [Related]
38. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
39. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I
Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis.
Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Avihingsanon Y; Assawasaksakul N; Kittanamongkolchai W
Lupus Sci Med; 2022 Jul; 9(1):. PubMed ID: 35902168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
